Gyre Therapeutics Inc
GYRE6.780USD
+0.130+1.95%
시장 운영 시간 （ET）시세는 15분 지연됩니다
594.17M시가총액
81.94P/E TTM
자세한 내용은 Gyre Therapeutics Inc 회사
Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The Company is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. The Company operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. The Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States.
회사 정보
종목 코드 GYRE
회사 이름Gyre Therapeutics Inc
상장일Apr 12, 2006
CEODr. Han Ying, Ph.D.
직원 수574
유형Ordinary Share
회계 연도 종료Apr 12
주소12770 High Bluff Drive, Suite 150
도시SAN DIEGO
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호92130
전화16199493681
웹사이트https://www.gyretx.com/
종목 코드 GYRE
상장일Apr 12, 2006
CEODr. Han Ying, Ph.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Songjiang Ma
Mr. Songjiang Ma
President, Director
President, Director
2.84M
-3.64%
Mr. Weiguo Ye
Mr. Weiguo Ye
Chief Operating Officer
Chief Operating Officer
700.00K
+7.69%
Mr. Rodney L. Nussbaum
Mr. Rodney L. Nussbaum
Independent Director
Independent Director
--
--
Dr. David M. Epstein, Ph.D.
Dr. David M. Epstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Han Ying, Ph.D.
Dr. Han Ying, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Ruoyu Chen
Ms. Ruoyu Chen
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Mr. Thomas Eastling
Mr. Thomas Eastling
Director
Director
--
--
Mr. Ping Zhang
Mr. Ping Zhang
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Gordon G. Carmichael, Ph.D.
Mr. Gordon G. Carmichael, Ph.D.
Independent Director
Independent Director
--
--
Dr. Renate Parry, Ph.D.
Dr. Renate Parry, Ph.D.
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Songjiang Ma
Mr. Songjiang Ma
President, Director
President, Director
2.84M
-3.64%
Mr. Weiguo Ye
Mr. Weiguo Ye
Chief Operating Officer
Chief Operating Officer
700.00K
+7.69%
Mr. Rodney L. Nussbaum
Mr. Rodney L. Nussbaum
Independent Director
Independent Director
--
--
Dr. David M. Epstein, Ph.D.
Dr. David M. Epstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Han Ying, Ph.D.
Dr. Han Ying, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Ruoyu Chen
Ms. Ruoyu Chen
Chief Financial Officer
Chief Financial Officer
--
-100.00%
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sun, Jul 6
마지막 업데이트: Sun, Jul 6
주주
주주 유형
주주
주주
비율
GNI Group Ltd
82.60%
Luo (Ying)
3.22%
Ma (Songjiang)
3.22%
The Vanguard Group, Inc.
1.24%
Ye (Weiguo)
0.79%
Other
8.92%
주주
주주
비율
GNI Group Ltd
82.60%
Luo (Ying)
3.22%
Ma (Songjiang)
3.22%
The Vanguard Group, Inc.
1.24%
Ye (Weiguo)
0.79%
Other
8.92%
주주 유형
주주
비율
Corporation
82.60%
Individual Investor
7.26%
Investment Advisor
2.11%
Investment Advisor/Hedge Fund
0.69%
Research Firm
0.19%
Hedge Fund
0.02%
Other
7.14%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
123
81.82M
92.88%
+8.77M
2025Q1
126
82.96M
94.19%
+9.94M
2024Q4
117
71.62M
76.58%
-277.10K
2024Q3
117
71.44M
76.41%
-69.01K
2024Q2
108
71.18M
81.40%
+2.80M
2024Q1
95
70.73M
80.87%
+2.43M
2023Q4
101
67.57M
93.09%
+2.43M
2023Q3
124
846.01K
34.20%
-1.22M
2023Q2
137
853.88K
34.77%
-909.13K
2023Q1
173
927.40K
37.69%
-976.07K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
GNI Group Ltd
72.77M
82.6%
+8.77M
+13.70%
Mar 12, 2025
Luo (Ying)
2.84M
3.22%
--
--
Sep 06, 2024
Ma (Songjiang)
2.84M
3.22%
-107.21K
-3.64%
Mar 12, 2025
The Vanguard Group, Inc.
1.10M
1.24%
+774.02K
+240.03%
Mar 31, 2025
Ye (Weiguo)
700.00K
0.79%
+50.00K
+7.69%
Apr 01, 2025
BlackRock Institutional Trust Company, N.A.
506.93K
0.58%
+12.53K
+2.53%
Mar 31, 2025
Geode Capital Management, L.L.C.
312.32K
0.35%
+8.22K
+2.70%
Mar 31, 2025
State Street Global Advisors (US)
128.77K
0.15%
+2.13K
+1.68%
Mar 31, 2025
SBI Securities Co., Ltd.
123.63K
0.14%
+22.39K
+22.12%
Mar 31, 2025
Charles Schwab Investment Management, Inc.
111.42K
0.13%
-3.15K
-2.75%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
iShares Russell 2000 Growth ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
ProShares UltraPro Russell2000
0%
Schwab U.S. Small-Cap ETF
0%
iShares Morningstar Small-Cap Value ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
FlexShares Morningstar US Market Factor Tilt Index Fund
0%
iShares Russell 2000 Value ETF
0%
더 보기
iShares Russell 2000 Growth ETF
비율0.01%
iShares Core S&P Total U.S. Stock Market ETF
비율0%
ProShares UltraPro Russell2000
비율0%
Schwab U.S. Small-Cap ETF
비율0%
iShares Morningstar Small-Cap Value ETF
비율0%
iShares Russell 2000 ETF
비율0%
Avantis US Small Cap Equity ETF
비율0%
ProShares Hedge Replication ETF
비율0%
FlexShares Morningstar US Market Factor Tilt Index Fund
비율0%
iShares Russell 2000 Value ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Oct 30, 2023
Merger
15<1
Oct 30, 2023
Merger
15<1
Oct 30, 2023
Merger
15<1
Oct 30, 2023
Merger
15<1
날짜
유형
비율
Oct 30, 2023
Merger
15<1
Oct 30, 2023
Merger
15<1
Oct 30, 2023
Merger
15<1
Oct 30, 2023
Merger
15<1
